Results 31 to 40 of about 5,430 (178)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak   +14 more
doaj   +1 more source

Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).

, 2021
Characteristics of patients completed sofosbuvir-daclatasvir treatment cascade (n = 184).
Kuntjoro Harimurti (10035887), Evy Yunihastuti (428215), Andri Sanityoso Sulaiman (10881067), Rahmat Hariyanto (11268731)   +3 more
core   +1 more source

Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico

Annals of Hepatology, 2022
Introduction and Objectives: Death due to liver damage caused by hepatitis C virus (HCV), this agent represents one of the most frequent health threats in Mexico.
K López-Riojas, KA Galán-Huerta, AF Ruiz-Higareda, L Muñoz-Espinosa, P Cordero-Pérez, D Arellanos-Soto, S Lozano-Sepúlveda, AM Rivas-Estilla   +7 more
doaj   +1 more source

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Gut and Liver, 2018
Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection.
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park   +10 more
doaj   +1 more source

Terapi Kombinasi Sofosbuvir dan Daclatasvir Pada Pasien dengan Hepatitis C Kronik : Sebuah Tinjauan Literatur

, 2023
Latar Belakang: Hepatitis C kronik merupakan penyakit hati yang disebabkan oleh virus hepatitis c/HCV. World Health Organization/WHO melaporkan bahwa lebih dari 3% populasi dunia terinfeksi HCV.
Ary Susilo, Samuel, Hermanto Saputra, Antonius, Derrel Wunnarchie, Malvincent, Odyssey Saint, Hayuningrat, Fitriyah Ashari, Shoimatul   +4 more
core   +1 more source

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen

Kidney International Reports, 2017
There is paucity of data on sofosubvir (SOF)−based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India.
Sanjay Kumar Agarwal, Soumita Bagchi, Raj Kumar Yadav   +2 more
doaj   +1 more source

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

One Health & Risk Management, 2020
Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU, Liliana HODOROGEA, Tiberiu HOLBAN   +2 more
doaj   +1 more source

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 [PDF]

, 2021
Background: Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality.
Souza, TML, Rajoli, RKR, Ju, J, Garzia, A, Bou-Habib, DC, Da Silva, ADPD, Ferreira, MA, Xie, W, De Freitas, CS, Bastos, MME, Pedrosa, CSG, Temerozo, JR, Boechat, N, Bozza, PT, Vitória, G, Guimarães, MZ, Bozza, FA, Wang, X, Dias, SDSG, Owen, A, Goto-Silva, L, Souza, LRQ, Chien, M, Soares, VC, Patel, D, Tao, C, Rehen, SK, Hoelz, LVB, Jockusch, S, Tuschl, T, Russo, JJ, Branco, FSC, Da Silva, CDS, Fernandes, TVA, Sacramento, CQ, Fintelman-Rodrigues, N, Pão, CRR, Ferreira, AC, Mattos, M, Saraiva, FB   +39 more
core   +1 more source

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture

Frontiers in Microbiology, 2022
We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection.
Carlos García-Crespo, Carlos García-Crespo, Lucía Vázquez-Sirvent, Lucía Vázquez-Sirvent, Pilar Somovilla, Pilar Somovilla, María Eugenia Soria, María Eugenia Soria, María Eugenia Soria, Isabel Gallego, Isabel Gallego, Ana Isabel de Ávila, Ana Isabel de Ávila, Brenda Martínez-González, Brenda Martínez-González, Antoni Durán-Pastor, Esteban Domingo, Esteban Domingo, Celia Perales, Celia Perales, Celia Perales, Celia Perales   +21 more
doaj   +1 more source